Xenical orlistat gastrointestinal lipase inhibitor: Roche published in The Lancet results of a double-blind, placebo-controlled trial in 688 patients (BMI 28-47

By WIR Staff | Jul 20, 1998 | 7:00 AM GMT

In the first year, the orlistat group lost an average of 10.3 kg compared

Read the full 147 word article

How to gain access

Continue reading with a
two-week free trial.